ECI® Clinical Trial Results
Trial Data. Revealed.
Results of the ECI® osteosarcoma treatment were published in the Journal of Veterinary Internal Medicine (July 2020) with the researchers determining it to be safe and tolerable in the study. Median Survival Time for dogs completing the osteosarcoma protocol was 415 days. It was further noted that this median survival time exceeded those typically reported for those patients receiving amputation plus chemotherapy. The promise of improved survival rates and prolonged life for cancer patients is being revealed in the data.
Autologous cancer cell vaccination, adoptive T‐cell transfer, and interleukin‐2 administration results in long‐term survival for companion dogs with osteosarcoma
Brian K. Flesner, Gary W. Wood, Pamela Gayheart‐Walsten, F. Lynn Sonderegger, Carolyn J. Henry, Deborah J. Tate, Sandra M. Bechtel, Lindsay L. Donnelly, Gayle C. Johnson, Dae Young Kim, Tammie A. Wahaus, Jeffrey N. Bryan, Noe Reyes
First published 10 July 2020
Real Cancer Patients. Helped.
While the data is promising, the effect on the lives of beloved dogs is truly inspiring. Families have also gained more quality time with their cherished companions. This is why we’re working so hard to advance cancer therapy in dogs.
Read the case studies below
